SCHEMBL1924407

SCHEMBL1924407

Cc1ccc(NC(=O)Nc2cccc(C(=O)c3cc(C(C)C)n4ncnc(N)c34)c2)c(C)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 5/20 0.79
▸ NTRK2 Q16620 6/20 0.75
▸ AURKA O14965 3/20 0.45
▸ AURKB Q96GD4 3/20 0.45
▸ ERBB4 Q15303 5/20 0.45
▸ EGFR P00533 4/20 0.45
▸ TEK Q02763 3/20 0.45
▸ ERBB2 P04626 3/20 0.45
▸ ERBB3 P21860 3/20 0.45
▸ PDGFRB P09619 1/20 0.43
▸ KDR P35968 5/20 0.40
▸ LCK P06239 2/20 0.39
▸ FYN P06241 2/20 0.39
▸ LYN P07948 2/20 0.39
▸ PIM1 P11309 2/20 0.39
▸ MARK3 P27448 2/20 0.39
▸ FLT3 P36888 2/20 0.39
▸ MAPK9 P45984 2/20 0.39
▸ GSK3A P49840 2/20 0.39
▸ GSK3B P49841 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14537180 0.92 NTRK2 (0.86) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1924099 0.92 NTRK1 (0.85) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1924937 0.91 NTRK1 (0.88) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1925208 0.91 NTRK1 (0.89) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1925238 0.90 NTRK2 (0.78) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1924770 0.90 NTRK1 (0.77) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1924415 0.89 NTRK1 (0.86) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1924668 0.89 NTRK1 (0.74) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1924757 0.89 NTRK1 (1.00) NTRK1NTRK2AURKAAURKBERBB4
SCHEMBL1925957 0.87 NTRK1 (0.77) NTRK1NTRK2AURKAAURKBERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948664-B1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-06-08 — — EP claimed
US-7514435-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-07 — — US claimed
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 — — US claimed
EP-1948664-B1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-06-08 — — EP disclosed
US-7514435-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-04-07 — — US disclosed
EP-1948664-A2 PYRROLOTRIAZINE KINASE INHIBITORS Brystol-Myers Squibb Company (US) 2008-07-30 — — EP disclosed
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 — — US disclosed
WO-2007061882-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149534-A1 PYRROLOTRIAZINE KINASE INHIBITORS NTRK2, NTRK3, NTRK1 NTRK1 3/4885NTRK2 1/4885AURKA 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback